Hematology/Oncology

• In the Journals

• Low-intensity warfarin reduces bleeding, symptomatic venous thromboembolism after THA

• May 16, 2013
• Researchers in this study reported low rates of symptomatic venous thromboembolism and clinically relevant bleeding 90 days after using low-intensity...More »

• Meeting News Coverage Perspective

• BRUISE CONTROL: Surgery with continued warfarin reduced adverse outcomes

• May 10, 2013
• DENVER — A strategy of continued warfarin during implantable cardioverter defibrillator or pacemaker surgery reduced the incidence of device-pocket...More »

• Meeting News Coverage

• CLABSI rate in children increased according to condition complexity

• May 9, 2013
• WASHINGTON —­­ Central line-associated bloodstream infection rates can be determined by condition groups, and reporting can reflect differences in...More »

• CME

• Electro-Gene Therapy with IL-12 Plasmid in Metastatic Melanoma

• This activity will discuss the safety, efficacy, and side effects of IL-12, as shown in Phase I and Phase II studies…...More »
• This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

• In the Journals

• Intraoperative tranexamic acid reduced need for transfusion in TJA

• May 7, 2013
• In this study, Italian researchers concluded that tranexamic acid lowered the transfusion risk in patients undergoing joint arthroplasty.
  “The...More »

• In the Journals Perspective

• Preoperative transfusion reduced perioperative complications in sickle cell disease

• May 3, 2013
• Preoperative transfusion reduced perioperative complications by nearly 25% in a cohort of patients with sickle cell disease, according to results of a...More »

• CME

• Does Biochemotherapy Have a Role in Adjuvant Therapy?

• This activity will discuss the role of biochemotherapy in adjuvant therapy when treating high-risk melanoma patients…...More »
• This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

• CME

• Debate: “Interferon Sensitivity”: Adjuvant IFN Should Be Used Only in Patients with Ulceration and/or Microscopic Nodal Disease

• This activity will feature two experts debating the efficacy of high-dose, intermediate-dose and low-dose interferon in melanoma patients in various disease stages and with certain characteristics,…...More »
• This activity is supported by educational grants from Bristol-Myers Squibb, Delcath Systems, Inc., Merck & Co., Inc., OncoSec Medical, Inc., Prometheus and Provectus Pharmaceuticals, Inc.

• Pradaxa prescribing information updated

• April 30, 2013
• The labeling for dabigatran, an oral anticoagulant indicated to reduce the risk for stroke and systemic embolism in patients with nonvalvular atrial...More »

• FDA approvals Perspective

• FDA approved Kcentra for urgent reversal of anticoagulation

• April 30, 2013
• The FDA approved the use of Kcentra for the urgent reversal of vitamin K antagonist anticoagulation in adults with acute major bleeding.
  Kcentra (CSL...More »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!